Hepatitis B Virus Surface Antigen Confirmation, Prenatal
Also known as: HBSAGCONPN
Use
This test is used for the confirmation of the presence of hepatitis B surface antigen (HBsAg) in prenatal specimens, particularly for pregnant women who have screened reactive for HBsAg. It is intended to provide confirmation of the initial reactive screening result to ensure accurate diagnosis and management of hepatitis B infection during pregnancy.
Special Instructions
Not provided.
Limitations
This assay should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular- and tissue-based products (HCT/P). False positives may occur, and if the result is not supported by clinical evidence, repeat testing of a new sample is recommended to clarify the diagnosis.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
Hepatitis B Surface Antigen (HBsAg)
Protein
LOINC Codes
- 65633-0 - HBV surface Ag SerPl Ql Cfm
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.5 mL
Minimum Volume
1.5 mL
Container
ARUP standard transport tube
Collection Instructions
Collect using a serum separator tube. Pink (K2EDTA) tube is also acceptable but avoid using heparinized plasma.
Storage Instructions
Refrigerated storage is required.
Causes for Rejection
Heparinized plasma, specimens containing particulate material or obvious microbial contamination, heat-inactivated, severely hemolyzed or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 week |
| Frozen | Indefinitely |
Other tests from different labs that may be relevant